Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett DR, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM. Phadke MS, et al. Among authors: eroglu z. Cancer Immunol Res. 2021 May;9(5):554-567. doi: 10.1158/2326-6066.CIR-20-0905. Epub 2021 Mar 2. Cancer Immunol Res. 2021. PMID: 33653716 Free PMC article.
Combination Therapies for Melanoma: A New Standard of Care?
Smalley KS, Eroglu Z, Sondak VK. Smalley KS, et al. Among authors: eroglu z. Am J Clin Dermatol. 2016 Apr;17(2):99-105. doi: 10.1007/s40257-016-0174-8. Am J Clin Dermatol. 2016. PMID: 26860106 Free PMC article. Review.
Improving patient outcomes to targeted therapies in melanoma.
Eroglu Z, Smalley KS, Sondak VK. Eroglu Z, et al. Expert Rev Anticancer Ther. 2016 Jun;16(6):633-41. doi: 10.1080/14737140.2016.1178575. Epub 2016 May 12. Expert Rev Anticancer Ther. 2016. PMID: 27137746 Review.
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Algazi AP, et al. Among authors: eroglu z. Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17. Cancer. 2016. PMID: 27533448 Free PMC article.
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. Shoushtari AN, et al. Among authors: eroglu z. Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17. Cancer. 2016. PMID: 27533633 Free PMC article.
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Menzies AM, et al. Among authors: eroglu z. Ann Oncol. 2017 Feb 1;28(2):368-376. doi: 10.1093/annonc/mdw443. Ann Oncol. 2017. PMID: 27687304 Free article.
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Zimmer L, et al. Among authors: eroglu z. Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17. Eur J Cancer. 2017. PMID: 28214657 Clinical Trial.
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D. Shiuan E, et al. Among authors: eroglu z. J Immunother Cancer. 2017 Feb 21;5:8. doi: 10.1186/s40425-017-0210-0. eCollection 2017. J Immunother Cancer. 2017. PMID: 28239462 Free PMC article.
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI. Wang DY, et al. Among authors: eroglu z. Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10. Cancer Immunol Res. 2017. PMID: 28396509 Free PMC article.
150 results